A government advisory panel in a split vote on June 26 advised the Centers for Disease Control and Prevention to recommend an antibody against respiratory syncytial virus (RSV) for many infants younger than 8 months of age.
In the first vote from the Advisory Committee on Immunization Practices (ACIP) since it was remade by Health Secretary Robert F. Kennedy Jr., a majority of members said they favor making an antibody made by Merck called clesrovimab available to all infants, regardless of underlying health.
Martin Kulldorff and Drs. Joseph Hibbeln, Robert Malone, Cody Meissner, and James Pagano voted yes.
The vote means that, if the advice is adopted, the CDC will recommend receipt of an antibody to infants younger than 8 months of age whose mothers did not receive an RSV vaccination while pregnant….